China NMPA's CDE has approved Alphamab Oncology’s IND for the multicentre Phase I/II JSKN033-102 trial of JSKN033.

RAG-17 is tailored for the SOD1 gene suppression in individuals with ALS having pathogenic mutations. Credit: CC7/Shutterstock. Ractigen Therapeutics has dosed the first subject in the randomised ...

XBiotech has said it will investigate the results of its rheumatoid arthritis trial after finding irregularities in its Phase II trial.

The investigational therapy works to impede the expression of genes that cause the body to store fat as a potential treatment for obesity.

Modified Rodnan Skin Score is the primary endpoint of the TibuSURE trial. Credit: Cesare Andrea Ferrari/Shutterstock. Zura Bio has initiated the double-blind Phase II TibuSURE trial to assess the ...

Marengo's Phase II trial is assessing T cell activator invikafusp alfa in the treatment of advanced PD-1 resistant solid tumours.

Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying antirheumatic drugs.

AI continued to be shown as an invaluable tool with the potential to accelerate clinical trials and improve patient care.

There have been several impactful clinical trial read outs in 2024. Image credit: Shutterstock / Rajitha Tennakoon From gene therapies to psychedelics and cancer vaccines to HIV pre-exposure ...

Jemperli is central to GSK’s immuno-oncology research and development efforts. Credit: GSK. GSK has reported that the double-blind, randomised Phase III FIRST-ENGOT-OV44 trial of Zejula (niraparib) ...